Seroprevalence of SARS-CoV-2 IgG in people with cystic fibrosis

Heliyon, Journal Year: 2024, Volume and Issue: 10(6), P. e27567 - e27567

Published: March 1, 2024

BackgroundWhen the first known US case of COVID-19 (Coronavirus Disease 2019) was reported in early 2020, little about impact this novel virus on cystic fibrosis community. As majority individuals with CF have chronic lung disease, population initially considered to be at high risk for severe disease as infection a multitude viruses has proven cause pulmonary exacerbation. SARS-CoV-2 challenging study given multiple manifestations, range severity, and wave-like phenomenon that varies geographically. People who become infected can asymptomatic or symptoms ranging from mild cough congestion full respiratory failure, similar manifestations seen non-CF individuals. By studying seroprevalence, clinical course, antibody durability due vaccinations, we will better equipped provide appropriate informed care people CF.MethodsBetween July 2020 April 2021 enrolled 123 (pwCF) receive MN Center. We monitored their serology every 6 months immunoglobulins (nucleocapsid spike IgG) evidence natural induced immunity. Medication use, function, exacerbation history, hospitalizations were extracted via electronic medical record (EMR).Results84% (101/120) participants vaccinated against during study. Eighty three percent cohort showed either "immunity." The average duration immunity 6.1 7.4 an overall 6.8 months. Earliest detected 12 days after single dose BNT162b2 vaccine detectable across span 13 Eleven did not measurable IgG. 36% non-responders (NRs) solid organ transplant patients immunosuppressive therapy. Only 3 within hospitalized COVID pneumonia all survived.ConclusionTo our knowledge, is report seroprevalence longevity IgG 1 year adults widespread availability vaccinations. These data show pwCF respond vaccination produce long-lasting antibodies general population.

Language: Английский

---

Covid-19 in cystic fibrosis patients compared to the general population: Severity and virus-host cell interactions

Journal of Cystic Fibrosis, Journal Year: 2024, Volume and Issue: 23(4), P. 625 - 632

Published: July 1, 2024

Language: Английский

---

Loss of CFTR Reverses Senescence Hallmarks in SARS-CoV-2 Infected Bronchial Epithelial Cells

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(11), P. 6185 - 6185

Published: June 4, 2024

SARS-CoV-2 infection has been recently shown to induce cellular senescence in vivo. A senescence-like phenotype reported cystic fibrosis (CF) models. Since the previously published data highlighted a low impact of on CFTR-defective cells, here we aimed investigate hallmarks context loss CFTR expression/function. We infected WT and KO 16HBE14o-cells with analyzed both p21 Ki67 expression using immunohistochemistry viral gene real-time PCR. Prior infection, cells displayed higher lower than cells. detected lipid accumulation identified as lipolysosomes residual bodies at subcellular/ultrastructure level. After situation reversed, high expression, well reduced Thus, activation pathways was reversed by while they were activated These uncover different response CF non-CF bronchial epithelial cell models contribute uncovering molecular mechanisms behind clinical COVID-19 patients.

Language: Английский

---

Clinical Outcomes Following SARS-CoV-2 Infection in Pediatric Cystic Fibrosis Patients

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: June 21, 2024

Background Cystic fibrosis (CF) is a genetic disorder of the cystic transmembrane conductance regulator chloride channel that leads to impaired mucus clearance in airways, which deteriorations lung function and chronic respiratory infection. These effects CF contribute hypothesis patients with may be at increased risk complications when they catch coronavirus disease 2019 (COVID-19), swept world global pandemic starting 2019. Overall, however, role COVID-19 has not been well studied, particularly pediatric patients. Methods In this retrospective review, who contracted (3/1/2020-3/1/2023) (N=69) were compared two equally sized control cohorts only or matched based on demographics clinical baselines. Occurrences adverse outcomes (emergency room visits, hospitalizations, pulmonary exacerbations, etc.) assessed for each subject. The mean percentage predicted forced expiratory volume 1 second (FEV1%pred) was also Fisher's exact test differences between proportions subjects experienced outcome. Independent two-variable t-testing FEV1%pred differences. Analysis conducted using IBM SPSS Statistics Windows, Version 29 (Released 2023; Corp., Armonk, New York, United States) significance α=0.05. Ad hoc power analysis G*Power v3.1. Results CF/COVID fared similarly groups without either history, including among subgroups stratified baseline function, P. aeruginosa colonization status, vaccination status. One notable finding significantly fewer exacerbations CF-only (p=0.004). Conclusion conclusion, performed their peers regard generally did demonstrate significant following Lower incidence could explained by stringent monitoring parents, quarantine, close pulmonology follow-up. findings will provide guidance management care COVID-19.

Language: Английский

---

Bronchial epithelial cells in cystic fibrosis: What happens in SARS-CoV-2 infection?

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 259 - 268

Published: Jan. 1, 2024

Language: Английский

---